HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

Kristof Theys, Jurgen Vercauteren, J. Snoeck, Maurizio Zazzi, Ricardo Camacho, Carlo Torti, Eugene Schulter, Bonaventura Clotet, Anders Sönnerborg, Andrea De Luca,

Antimicrobial Agents and Chemotherapy · 2012 · 41 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

References

9